Search trials – HealthDB

Активни:

Намерени 282 изпитвания Стр. 8 от 15

Active (not recruiting) Phase 2

J6E-MC-KWAN: A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

Trial status: Authorised The proportion of participants who achieve clinical remission with mMS at Week 12

Начало: 18.03.2026 Възраст: от 18 г.

Austria, Denmark, Germany +6 Eli Lilly & Co. 2025-522338-30-00

Active (not recruiting) Phase 1

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

Trial status: Authorised

Начало: 17.03.2026 Възраст: от 18 г.

France, Ireland, Spain Olema Pharmaceuticals Inc. 2025-523686-15-00

Active (not recruiting) Phase 3

A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants

Focal segmental glomerulosclerosis

Trial status: Authorised Key secondary endpoint: Absolute change in eGFRcys in mL/min/1.73m2 from baseline to Week 104, Key secondary endpoint: Treatment response, defined as 24-hr UPCR

Начало: 17.03.2026 Възраст: от 18 г.

Belgium, Croatia, Denmark +12 Boehringer Ingelheim International GmbH, Boehringer Ing 2025-522191-86-00

Active (not recruiting) Phase 1

A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults

CCI

Trial status: Authorised

Начало: 16.03.2026 Възраст: от 18 г.

Bulgaria, Croatia, Czech Republic +3 UCB Biopharma 2025-522782-30-00

Active (not recruiting) Phase 3

ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Participants with Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Previously Untreated Advanced or Metastatic Gastric Gastroesophageal Junction or Esophageal Adenocarcinoma

Trial status: Authorised (Phase 2): PFS (progression-free survival) by RECIST v1.1 per investigator assessment, defined as the time between the randomization date and the date of first documented tumor progression or death from any cause (whichever occurs first), (Phase 3): Duration of response (Partial Response or Complete Response) by RECIST v1.1 per investigator assessment, defined as the time between the date of the first documentation of objective tumor response (Complete Response or Partial Response) and the date of disease progression or to death from any cause (whichever occurs first), (Phase 2): Time to response (Complete Response or Partial Response) by RECIST v1.1 per investigator assessment, defined as the time between randomization to the date of the first documentation of objective tumor response, (Phase 2): Disease control (Best overall response of confirmed Complete Response, confirmed Partial Response, or Stable Disease) by RECIST v1.1 per investigator assessment, (Phase 2): Recommended dose of pumitamig for Phase 3, (Phase 3): Objective Response by RECIST v1.1 per BICR, (Phase 3): Duration of response by RECIST v1.1 per BICR (Phase 2): ORR, to compare how two different doses of the study drug affect tumor growth to help select the better dose., (Phase 3): PFS (progression-free survival) by BICR (Blinded Independent Central Review) The ability of Pumitamig to work better than current standard treatment by assessing how long it takes before the cancer starts growing again by radiographic imaging techniques (like CT scans)., (Phase 3): OS (Overall Survival) This study will assess if people live longer when they take Pumitamig compared to other standard treatment. This is what is called "Overall Survival".

Начало: 10.03.2026 Възраст: от 18 г.

France, Germany, Italy +3 Bristol-Myers Squibb Services Unlimited Company 2025-523263-37-00

Active (not recruiting) Phase 3

REVEAL Study: Phase 3 Study of the Efficacy and Safety of ION582 in Children and Adults with Angelman Syndrome

Angelman syndrome

Trial status: Authorised 1. Change in Bayley Scales for Infant and Toddler Development-4 (Bayley-4): Cognition Subdomain Raw Score without caregiver input [Time Frame: Baseline and Week 52], 2. Change in Symptoms of Angelman Syndrome -Clinician Global Impression of Change (SAS-CGI-C): Overall AS [Time Frame: Baseline and Week 52], 3. Change in Vineland Adaptive Behavior Scale-3 (Vineland-3): Receptive Communication Subdomain Raw Score [Time Frame: Baseline and Week 52], 4. Change in Vineland Adaptive Behavior Scale-3 (Vineland-3): Daily Living Skills, Personal Subdomain Raw Score [Time Frame: Baseline and Week 52], 5. Change in Symptoms of Angelman Syndrome - Clinician Global Impression of Change (SAS-CGI-C): Sleep Problems [Time Frame: Baseline and Week 52], 6. Change in Bayley Scales for Infant and Toddler Development-4 (Bayley-4): Fine Motor Subdomain Raw Score without caregiver input [Time Frame: Baseline to Week 52], 7. Change in Observer-Reported Communication Ability (ORCA): Overall Emerging T score [Time Frame: Baseline and Week 52], 8. Percentage of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [Time Frame: Up to Week 52], 9. Change in Vital Signs and Clinical Laboratory Results [Time Frame: Baseline and Week 52] Change in performance on the Expressive Communication subdomain raw score of the Bayley Scales for Infant and Toddler Development-4 (Bayley-4) without caregiver input in Cohort 1 [Time Frame: Baseline and Week 52]

Начало: 09.03.2026 Възраст: 18–64 г.

Germany, Italy, Poland +1 Ionis Pharmaceuticals Inc. 2024-519711-33-01

Active (not recruiting) Phase 2

A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

Trial status: Authorised Confirmed Composite Response Rate (RR), Confirmed prostate-specific antigen 90 (PSA90), Confirmed prostate-specific antigen 50 (PSA50), Objective Response Rate (ORR), Duration of Response (DOR), Overall Survival (OS), Incidence and severity of adverse events, with severity determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0), Change from baseline in selected vital signs, Change from baseline in selected clinical laboratory test results Radiographic Progression-Free Survival (rPFS)

Начало: 06.03.2026 Възраст: от 18 г.

France, Germany, Italy +1 F. Hoffmann-La Roche AG 2025-521327-67-00

Active (not recruiting) Phase 3

A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Secondary progressive multiple sclerosis

Trial status: Authorised Time to 3-month confirmed disability progression (3mCDP) on EDSS (key secondary), Time to 6-month confirmed disability improvement (6mCDI) on EDSS (key secondary), Time to 3-month worsening by at least 20% in Timed 25-Foot Walk (T25FW) (key secondary), Time to 3-month worsening by at least 20% in 9-Hole Peg Test (9-HPT) (key secondary), Annualized rate of new or enlarging T2 lesions (key secondary), Percentage of participants with annualized rate of brain atrophy > XX (key secondary), Time to 6-month worsening by at least 4 points in Symbol Digit Modalities Test (SDMT), Adverse events, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating Scale (C-SSRS) Time to 6-month confirmed disability progression (6mCDP) on Expanded Disability Status Scale (EDSS)

Начало: 03.03.2026 Възраст: от 18 г.

Austria, Belgium, Bulgaria +20 Novartis Pharma AG 2025-521546-23-00

Active (not recruiting) Phase 2

A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease

Complement-Mediated Kidney Disease

Trial status: Authorised 1. Change from baseline in UPCR as measured by 24-hour urine over time, 2. Change from baseline in UPCR as measured by spot urine over time Incidence and severity of TEAEs

Начало: 02.03.2026 Възраст: от 18 г.

Italy, Spain Adarx Pharmaceuticals Inc. 2025-521752-26-00

Active (not recruiting) Phase 3

HighLiGHts - A Pivotal, Parallel-Arm, Phase 3, Open-Label, Active-controlled, Global, Multicenter, Randomized Basket Trial Investigating the Efficacy and Safety of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Children and Adolescents with Growth Failure or Short Stature due to Growth Hormone Sufficient Disorders – Turner Syndrome, SHOX Deficiency, Small for Gestational Age, and Idiopathic Short Stature

short stature homeobox containing gene deficiency (SHOX-D) Turner Syndrome (TS) idiopathic short stature (ISS) small for gestational age (SGA)

Trial status: Authorised AHV (Week 104), Change from baseline in height SDS (CDC-based) (Weeks 52 and 104), Change from baseline in height SDS (condition specific if applicable) (Weeks 52 and 104), Treatment-emergent adverse events (AEs), Safety labs, vital signs, physical exam, local tolerability assessments, and fundoscopy, Bone age (Weeks 52 and 104), Bone age:chronological age ratio (Weeks 52 and 104) Annualized height velocity (AHV) at Week 52

Начало: 27.02.2026

France, Germany, Italy +2 Ascendis Pharma Endocrinology Division A/S 2025-523079-44-00

Active (not recruiting) Phase 2

A double-blind, randomized, placebo-controlled, two arm, phase II clinical trial in parallel groups to evaluate the efficacy and tolerability of a rectal treatment with budesonide suppositories compared to placebo suppositories for amelioration of acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma

Acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma

Trial status: Authorised Percentage of participants with reduction in CTCAE grading for proctitis by one and by two score point(s) from Baseline to Visit 2 and Baseline to Visit 4, Time to first improvement in CTCAE grading for diarrhea after Baseline, where improvement is defined as a lower CTCAE grading compared to Baseline for at least three consecutive days, Percentage of participants with reduction in CTCAE grading for diarrhea by one and by two score point(s) from Baseline to Visit 2 and Baseline to Visit 4, Time to first improvement in CTCAE grading for rectal pain after Baseline, where improvement is defined as a lower CTCAE grading compared to Baseline for at least three consecutive days, Percentage of participants with reduction in CTCAE grading for rectal pain by one and by two score point(s) from Baseline to Visit 2 and Baseline to Visit 4, Time to first improvement in each CTCAE grading for further terms of the lower GI composite (fecal incontinence, lower GI hemorrhage, GI pain and other GIdisorder), where improvement is defined as a lower CTCAE grading compared to Baseline for at least three consecutive days, Percentage of participants with reduction in each CTCAE gradings for further terms of the lower GI composite (fecal incontinence, lower GI hemorrhage, GI pain and other GI-disorder) by one and by two score point(s) from Baseline to Visit 2 and Baseline to Visit 4, Course and change from Baseline in the SHS-GI sum score and sub-scores at Visit 2, 4, and 5, Course and change from Baseline in the PGI-S at Visit 2, 4, and 5, PGI-C at Visit 2 and 4, Course and change from Baseline in the EPIC Bowel Domain Score at Visit 2, 4, and 5, Therapeutic success at Visit 4, defined as complete relief or marked improvement of symptoms according to the PGA, Therapeutic benefit at Visit 4, defined as at least a slight improvement according to the PGA, Assessment of efficacy by investigator and participant at Visit 4, Percentage of participants who remained symptom-free for at least ten consecutive days at Visit 4, Percentage of participants who used rescue medication at Visit 4., Duration of rescue medication use at Visit 4, Assessment of tolerability by investigator and participant at Visit 4, Average daily bowel movement frequency within the treatment period, Percentage of days within the treatment period with pain during bowel movements, Percentage of days within the treatment period with mild pain during bowel movements, Percentage of days within the treatment period with moderate pain during bowel movements, Percentage of days within the treatment period with severe pain during bowel movements, Percentage of days within the treatment period with bloody stool, Percentage of days within the treatment period with mucous stool, Percentage of days within the treatment period with uncontrolled bowel movements, Percentage of days within the treatment period during which no pads were used due to uncontrolled bowel movement, Percentage of days within the treatment period during which pads were used sometimes due to uncontrolled bowl movement, Percentage of days within the treatment period during which pads were used most of the time due to uncontrolled bowl movement, Percentage of days within the treatment period during which symptoms interfered with daily life, Percentage of days within the treatment period during which symptoms interfered with daily functioning to the extent that self-care was impossible, Percentage of days within the treatment period during which medical intervention was required due to symptoms Time to first improvement in CTCAE grading for proctitis is defined as the number of days from Baseline to the first occurrence of a lower CTCAE grading compared to Baseline, sustained for at least three consecutive days

Начало: 26.02.2026 Възраст: от 18 г.

Austria, Germany Dr. Falk Pharma GmbH 2024-519359-27-00

Active (not recruiting) Phase 3

Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia

NPM1-m and KMT2A-r Acute Myeloid Leukemia

Trial status: Authorised Nonintensive Therapy Study - CR rate per the ELN 2022 criteria per Investigator assessment - Percentage of patients achieving centrally defined BM MRD negativity - Rates of CR+CRh per ELN 2022 per Investigator assessment, Intensive Therapy Study (7+3) - Percentage of patients achieving CR per ELN 2022 criteria with centrally defined BM MRD negativity (CRMRD-) - Overall survival (OS) Nonintensive Therapy Study - Overall survival (OS) Intensive Therapy Study (7+3) - EFS, defined as the time from randomization to treatment failurea, hematologic relapse following CR, or death from any cause, whichever comes first

Начало: 20.02.2026 Възраст: от 18 г.

Belgium, Czech Republic, France +7 Kura Oncology Inc. 2025-521314-25-00

Active (not recruiting) Phase 3

TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (hATTR-PN)

Hereditary transthyretin-mediated amyloidosis with polyneuropathy

Trial status: Authorised 1. Change from baseline in Norfolk Quality of Life Diabetic Neuropathy (Norfolk QoL-DN) total score compared to the external placebo group from the APOLLO study at Month 9, 2. Percent reduction in serum TTR levels in the nucresiran group compared to the in-study vutrisiran group through Month 9, 3. Change from baseline in modified body mass index (mBMI) compared to the external placebo group from the APOLLO study at Month 9, 4. Change from baseline in the following parameters compared to the external placebo group from the APOLLO study at Month 18: o mNIS+7; o Norfolk QoL-DN total score; o mBMI; o Rasch-built Overall Disability Scale R-ODS; o Timed 10-meter walk test (10-MWT), 5. Percent reduction in serum TTR levels in the nucresiran group compared to the in-study vutrisiran group through Month 18, 6. Percent reduction in serum TTR levels in the nucresiran group compared to the in-study vutrisiran group at Week 6 Change from baseline in the Modified Neuropathy Impairment Score +7 (mNIS+7) compared to the external placebo group from the APOLLO study at Month 9

Начало: 20.02.2026 Възраст: от 18 г.

Cyprus, France, Germany +6 Alnylam Pharmaceuticals Inc. 2025-522544-40-00

Active (not recruiting) Phase 3

A phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer (OPERA-02)

ER+ HER2- Advanced Breast Cancer

Trial status: Authorised 1. OS, 2. BIRC-assessed PFS, ORR, DOR and CBR, 3. Local Investigator-assessed ORR, DOR, CBR, 4. Safety and tolerability, assessed by AEs, SAEs, dose modifications, clinical laboratory parameters, ECGs, performance status, and vital sign measurements, 5. Plasma levels of palazestrant and ribociclib (in investigational arm) and of ribociclib (in control arm) at predefined intervals to establish PK parameters., 6. PRO endpoints, assessed using the EORTC QLQ- C30, EORTC QLQ-BR42 and EQ-5D-5L questionnaires, 7. Time from randomization to disease progression on first subsequent systemic anti-cancer therapy or death Local Investigator-assessed PFS (Progression-Free Survival)

Начало: 17.02.2026 Възраст: от 18 г.

Austria, Belgium, Czech Republic +10 Olema Pharmaceuticals Inc. 2025-522873-12-00

Active (not recruiting) Phase 2

A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AZD5148 for Prevention of Recurrence of Clostridioides difficile Infection in Individuals 18 Years of Age and Above

Recurrence of Clostridioides difficile Infection

Trial status: Authorised Sustained clinical cure (ie, achievement of initial clinical cure + no recurrent C. difficile infection) First occurrence of recurrent C. difficile infection

Начало: 16.02.2026 Възраст: от 18 г.

Denmark, France, Germany +5 AstraZeneca AB 2025-521416-19-00

Active (not recruiting) Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed AML with an NPM1 mutation (REVEAL-ND NPM1)

Newly Diagnosed AML with an NPM1 mutation

Trial status: Authorised OS: Defined as the time from the date of randomization to the date of death from any cause., EFS (Investigator-assessed): Defined as the time from the date of randomization to the date of Induction treatment failure, relapse or death due to any cause, whichever occurs first., MRDBM (-) CR rate: Defined as the percentage of participants with CR (Investigator-assessed) who achieve MRDBM (-) status by molecular assay, MRDPB (-) CR rate: Defined as the percent of participants with CR (Investigator assessed) who achieve MRDPB (-) status by molecular assay, MRDBM (-) CR rate: Defined as the percent of participants with CR who achieve MRDBM (-) status., CR rate (Investigator-assessed): Defined as the percentage of participants who achieve CR, CRc rate (Investigator-assessed): Defined as the rate of CR + CRh (complete remission with partial hematologic recovery) + Cri (complete remission with incomplete hematologic recovery)., ORR (Investigator-assessed): Defined as the rate of CR + CRh + CRi + MLFS (morphologic leukemia-free state) + PR (partial response)., Duration of CR: Defined as time from first date of first CR to relapse or death., Duration of CRc: Defined as time from first date of first CRc to relapse or death., DOR: Defined as time from date of first documented response (CR, CRh, CRi, PR, or MLFS) to the first documented relapse or death., • Frequency, duration, and severity of TEAEs (treatment-emergent adverse events), TRAEs (treatment-related adverse event), and SAEs. • Incidence and shifts from baseline of clinically significant clinical laboratory abnormalities. • Change from baseline in other observations related to safety, including ECGs, vital signs, and performance status. EFS: Defined as the time from the date of randomization to the date of Induction treatment failure, relapse or death due to any cause, whichever occurs first. MRDBM (-) CR rate: Defined as the percentage of participants with CR

Начало: 13.02.2026 Възраст: от 18 г.

Austria, Belgium, Czech Republic +9 Syndax Pharmaceuticals Inc. 2025-522279-27-00

Active (not recruiting) Phase 3

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Chronic inflammatory demyelinating polyneuropathy (CIDP)

Trial status: Authorised Change from baseline in I-RODS centile points score - up to 24 weeks (part A), Change from baseline in MRC-SS at week 24, Change from baseline in grip strength (3-day moving average) in the dominant hand at week 24, Time to reduction of ≥1 point from baseline in aINCAT score - up to 24 weeks, Time to increase of ≥1 point compared with baseline in aINCAT score up to week 24, Change from baseline in grip strength (3-day moving average) of both hands over time and change from baseline in grip strength (daily average) for both hands, Change from baseline in MRC-SS over time. Up to 96 weeks (Part B), Change from baseline in aINCAT score over time, Change from baseline in EQ-5D-5L over time, Change from baseline in RT-FSS over time, Change from baseline in BPI-SF over time, PGI-S values over time, PGI-C values over time, Incidence and prevalence of ADA against empasiprubart in serum, Incidence and prevalence of NAb against empasiprubart in serum, Incidence and severity of AEs, Incidence of SAEs, Clinically meaningful changes in laboratory parameters, ECG results, and vital signs, Absolute values and percentage change from baseline in free C2 and total C2 over time, Serum concentrations of empasiprubart over time, Reduction of ≥1 point in aINCAT over time, Increase of ≥1 point from baseline in aINCAT over time, Change from baseline in TUG at week 24 Reduction of ≥1 point compared with baseline in aINCAT score at week 24

Начало: 10.02.2026 Възраст: от 18 г.

Austria, Bulgaria, Czech Republic +12 Argenx 2025-520805-10-00

Active (not recruiting) Phase 1

A Phase 1/1b First-in-Human Study of BMS-986506 in ccRCC

Advanced Clear Cell Renal Cell Carcinoma

Trial status: Authorised

Начало: 09.02.2026 Възраст: от 18 г.

France, Spain Bristol-Myers Squibb Services Unlimited Company 2025-522543-18-00

Active (not recruiting) Phase 4

Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products

Metastatic Melanoma Advanced solid tumors Hepatocellular Carcinoma Melanoma

Trial status: Authorised Evaluation of delayed adverse event(s) will be based on the occurrence of: New malignancy(ies); New incidence or exacerbation of a pre-existing neurologic disorder; New incidence or exacerbation of a pre-existing rheumatologic or other autoimmune disorder; New incidence of a hematologic disorder; New incidence of infection related to RPx, New herpetic infection and presence of RPx detected in samples collected from herpetic lesions

Начало: 09.02.2026 Възраст: от 18 г.

France, Germany, Greece +2 Replimune Group Inc. 2025-521621-33-00

Active (not recruiting) Phase 2

A Phase 2 randomized, double-blind, placebo-controlled study to investigate efficacy, safety, immunogenicity, and pharmacokinetics, of GSK3862995B in participants with bronchiectasis

Bronchiectasis

Trial status: Authorised 1. Annualized rate of exacerbationsa, 2. Time to first exacerbation, 3. Annualized rate of severe exacerbations What is the percentage reduction in annualized exacerbation rate on GSK3862995B versus placebo, in adult patients with bronchiectasis and recurrent exacerbations or uncontrolled symptoms assuming no study treatment discontinuation occurred, change in maintenance SOC or use of prohibited medications.

Начало: 09.02.2026 Възраст: от 18 г.

Denmark, France, Germany +3 GSK PLC 2025-522892-27-00

1 … 6 7 8 9 10 … 15